828 related articles for article (PubMed ID: 29129488)
21. Myelodysplastic syndromes: Contemporary review and how we treat.
Gangat N; Patnaik MM; Tefferi A
Am J Hematol; 2016 Jan; 91(1):76-89. PubMed ID: 26769228
[TBL] [Abstract][Full Text] [Related]
22. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
24. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant.
Motabi IH; Ghobadi A; Liu J; Schroeder M; Abboud CN; Cashen AF; Stockler-Goldstein KE; Uy GL; Vij R; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1324-1329. PubMed ID: 27026249
[TBL] [Abstract][Full Text] [Related]
26. Evolving treatment options of myelodysplastic syndromes.
Verbeek W; Ganser A
Ann Hematol; 2001 Sep; 80(9):499-509. PubMed ID: 11669297
[TBL] [Abstract][Full Text] [Related]
27. Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Hashmi SK; Punia JN; Marcogliese AN; Gaikwad AS; Fisher KE; Roy A; Rao P; Lopez-Terrada DH; Ringrose J; Loh ML; Niemeyer CM; Rau RE
Pediatr Blood Cancer; 2019 Oct; 66(10):e27905. PubMed ID: 31250550
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia.
Loh ML
Br J Haematol; 2011 Mar; 152(6):677-87. PubMed ID: 21623760
[TBL] [Abstract][Full Text] [Related]
29. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia].
Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828
[TBL] [Abstract][Full Text] [Related]
30. Treatment advances for pediatric and adult onset neoplasms with monocytosis.
McCullough KB; Kuhn AK; Patnaik MM
Curr Hematol Malig Rep; 2021 Jun; 16(3):256-266. PubMed ID: 33728588
[TBL] [Abstract][Full Text] [Related]
31. Clinical outcome after failure of hypomethylating therapy for myelodysplastic syndrome.
Lee JH; Choi Y; Kim SD; Kim DY; Lee JH; Lee KH; Lee SM; Lee WS; Joo YD
Eur J Haematol; 2015 Jun; 94(6):546-53. PubMed ID: 25315896
[TBL] [Abstract][Full Text] [Related]
32. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
33. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Garcia-Manero G; Fenaux P
J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
[TBL] [Abstract][Full Text] [Related]
34. High-risk myelodysplastic syndromes: chemotherapy, transplantation, and beyond.
Gergis U; Wissa U
Curr Hematol Malig Rep; 2010 Jan; 5(1):1-8. PubMed ID: 20425390
[TBL] [Abstract][Full Text] [Related]
35. Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses.
Cruijsen M; Hobo W; van der Velden WJFM; Bremmers MEJ; Woestenenk R; Bär B; Falkenburg JHF; Kester M; Schaap NPM; Jansen J; Blijlevens NNM; Dolstra H; Huls G
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1000-1008. PubMed ID: 26860635
[TBL] [Abstract][Full Text] [Related]
36. Juvenile myelomonocytic leukemia.
Proytcheva M
Semin Diagn Pathol; 2011 Nov; 28(4):298-303. PubMed ID: 22195407
[TBL] [Abstract][Full Text] [Related]
37. Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.
Waespe N; Van Den Akker M; Klaassen RJ; Lieberman L; Irwin MS; Ali SS; Abdelhaleem M; Zlateska B; Liebman M; Cada M; Schechter T; Dror Y
Haematologica; 2016 Dec; 101(12):1508-1515. PubMed ID: 27540140
[TBL] [Abstract][Full Text] [Related]
38. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
39. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
[TBL] [Abstract][Full Text] [Related]
40. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
Sakashita K
Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]